These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 22038348)
21. Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies. Lesovaya E; Yemelyanov A; Kirsanov K; Popa A; Belitsky G; Yakubovskaya M; Gordon LI; Rosen ST; Budunova I Cell Cycle; 2013 Jan; 12(1):133-44. PubMed ID: 23255118 [TBL] [Abstract][Full Text] [Related]
22. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro]. Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063 [TBL] [Abstract][Full Text] [Related]
23. OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. Korotchkina L; Kazyulkin D; Komarov PG; Polinsky A; Andrianova EL; Joshi S; Gupta M; Vujcic S; Kononov E; Toshkov I; Tian Y; Krasnov P; Chernov MV; Veith J; Antoch MP; Middlemiss S; Somers K; Lock RB; Norris MD; Henderson MJ; Haber M; Chernova OB; Gudkov AV Leukemia; 2020 Jul; 34(7):1828-1839. PubMed ID: 31896781 [TBL] [Abstract][Full Text] [Related]
24. [Effects of human umbilical cord mesenchymal stem cells on the proliferation of hematopoietic malignancies]. Pang Y; Tang Y; Li Q; Xie J; Zang X; Liu T; Zhang B; Chen H Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jul; 29(7):714-8. PubMed ID: 23837982 [TBL] [Abstract][Full Text] [Related]
25. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Plasilova M; Zivny J; Jelinek J; Neuwirtova R; Cermak J; Necas E; Andera L; Stopka T Leukemia; 2002 Jan; 16(1):67-73. PubMed ID: 11840265 [TBL] [Abstract][Full Text] [Related]
26. The rise of apoptosis: targeting apoptosis in hematologic malignancies. Valentin R; Grabow S; Davids MS Blood; 2018 Sep; 132(12):1248-1264. PubMed ID: 30012635 [TBL] [Abstract][Full Text] [Related]
27. MUC18, a member of the immunoglobulin superfamily, is expressed on bone marrow fibroblasts and a subset of hematological malignancies. Filshie RJ; Zannettino AC; Makrynikola V; Gronthos S; Henniker AJ; Bendall LJ; Gottlieb DJ; Simmons PJ; Bradstock KF Leukemia; 1998 Mar; 12(3):414-21. PubMed ID: 9529137 [TBL] [Abstract][Full Text] [Related]
28. Nanomedicines for the treatment of hematological malignancies. Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140 [TBL] [Abstract][Full Text] [Related]
30. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Prabhu VV; Talekar MK; Lulla AR; Kline CLB; Zhou L; Hall J; Van den Heuvel APJ; Dicker DT; Babar J; Grupp SA; Garnett MJ; McDermott U; Benes CH; Pu JJ; Claxton DF; Khan N; Oster W; Allen JE; El-Deiry WS Cell Cycle; 2018; 17(4):468-478. PubMed ID: 29157092 [TBL] [Abstract][Full Text] [Related]
31. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
32. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies. Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758 [TBL] [Abstract][Full Text] [Related]
33. The peptide derived from the Ig-like domain of human herpesvirus 8 K1 protein induces death in hematological cancer cells. Daniluk U; Kerros C; Tao RH; Wise JF; Ao X; Berkova Z; Samaniego F J Exp Clin Cancer Res; 2012 Aug; 31(1):69. PubMed ID: 22929310 [TBL] [Abstract][Full Text] [Related]
34. Alterations of the PPP1R3 gene in hematological malignancies. Inoue K; Kohno T; Takakura S; Morishita K; Takita J; Hayashi Y; Mizoguchi H; Yokota J Int J Oncol; 2000 Oct; 17(4):717-21. PubMed ID: 10995882 [TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. Kessler T; Fehrmann F; Bieker R; Berdel WE; Mesters RM Curr Drug Targets; 2007 Feb; 8(2):257-68. PubMed ID: 17305503 [TBL] [Abstract][Full Text] [Related]
36. Hematologic Malignancies Discovered on Investigation of Breast Abnormalities. Alsadi A; Lin D; Alnajar H; Brickman A; Martyn C; Gattuso P South Med J; 2017 Oct; 110(10):614-620. PubMed ID: 28973700 [TBL] [Abstract][Full Text] [Related]
37. Identification and characterization of nonapeptide targeting a human B cell lymphoma, Raji. Choi JH; Lee WK; Han SH; Ha S; Ahn SM; Kang JS; Choi YJ; Yun CH Int Immunopharmacol; 2008 Jun; 8(6):852-8. PubMed ID: 18442789 [TBL] [Abstract][Full Text] [Related]
38. Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies. Cao L; Fan L; Xu W; Li JY Curr Cancer Drug Targets; 2015; 15(9):769-80. PubMed ID: 26567881 [TBL] [Abstract][Full Text] [Related]
39. Cytotoxic mechanisms of primin, a natural quinone isolated from Eugenia hiemalis, on hematological cancer cell lines. Bigolin A; Maioral MF; Stefanes NM; Zatelli GA; Philippus AC; Falkenberg MB; Santos-Silva MC Anticancer Drugs; 2020 Aug; 31(7):709-717. PubMed ID: 32639281 [TBL] [Abstract][Full Text] [Related]